Median Technologies to attend the 2019 ASCO Annual Meeting, May 31 – June 4, 2019, McCormick Place, Chicago, IL, USA

Sophia Antipolis, France

Press release – For immediate release – 5:45 pm CEST

Median Technologies to attend the 2019 ASCO Annual Meeting, May 31 – June 4, 2019, McCormick Place, Chicago, IL, USA

Median Technologies, The Imaging Phenomics Company®, announced today that it will be exhibiting at the 2019 ASCO Annual Meeting, May 31 – June 4 at the McCormick Place, Chicago, IL, USA (exhibition dates: June 1-3).

Median Technologies will share and showcase its offering for imaging solutions and services in clinical trials iSee® and present the latest developments of its imaging Phenomics platform iBiopsy®, at booth #6102.

The Median’s clinical team will be available at the booth to discuss the abstract results: “Imaging biomarker phenotyping system (iBiopsy) to accelerate hepatocellular carcinoma (HCC) drug development”. The abstract is online here.

The ASCO Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology, the largest oncology society in the world. Each year, the ASCO conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO Annual Meeting:

Download 20190521_PR_ASCO2019.pdf

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information:


Median Technologies

Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88

Actifin  (Investors)

Ghislaine Gasparetto
+33 6 21 10 49 24

Alizé RP  (Press)

Caroline Carmagnol
+33 6 64 18 99 59